Jeffrey Kurz

Jeffrey Kurz

Company: Alnylam Pharmaceuticals

Job title: Associate Director


Roundtable Discussion: Evaluating Utility & Clinical Acceptance of Promising Direct CNS Delivery Modalities 12:00 pm

More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas: What are the greatest safety risks to be mitigated to advance clinical utility of intra-CSF delivery methods? How can synergy between the drug and the administration device be improved to streamline development and approval of drug-device…Read more

day: Conference Day Two

Lost in Translation: Replicating Proof-of-Concept Studies for Intra-CSF Delivery Methods in Clinical Practice 11:05 am

Physiological cross species differences remain a critical barrier to scaling up doses across in vivo intra-CSF studies, therefore emphasizing the need to enhance translatability of rodent and non-human primate models to study CNS drug delivery. • How can we navigate differences in quality and preparation standards to successfully scale up injection doses from mouse to…Read more

day: Pre-Conference Track 2 AM

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.